Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CETIRIZINE HYDROCHLORIDE

All products: not a benefit

Other products in the same Health Canada class (R06A) — coverage varies; not interchangeable

  • Bilastine (Jamp Bilastine Oral Solution): not a benefit
  • Loratadine (Claritin): not a benefit
  • Rupatadine (Rupall): not a benefit

Reactine · DIN 01900978 · 20mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Reactine · DIN 01900978 Manufacturer: McNeil Consumer Products Co.; listing date 2008-12-23 Health Canada: Marketed since 2026-04-17 · brand REACTINE 20 MG TABLET · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 20 MG · company Kenvue canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Reactine: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=46803 · Verify on the e-Formulary ↗ (DIN 01900978)

Source record
DIN 01900978: Reactine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 040000087; group id 2; item number 0004; lccId None; manufacturer id MCL Source form: Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01900978 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=46803
Interchangeable products
Apo-Cetirizine · DIN 02453363 · not recorded Cetirizine · DIN 02515695 · not recorded Cetirizine · DIN 02534126 · not recorded Jamp Cetirizine Tablets · DIN 02517353 · not recorded Jamp-Cetirizine · DIN 02466171 · not recorded M-Cetirizine · DIN 02512025 · not recorded Mar-Cetirizine · DIN 02427141 · not recorded Mint-Cetirizine · DIN 02491125 · not recorded NRA-Cetirizine · DIN 02521806 · not recorded NRA-Cetirizine Tablets · DIN 02530236 · not recorded Nat-Cetirizine · DIN 02496488 · not recorded PMS-Cetirizine · DIN 02315963 · not recorded Teva-Cetirizine · DIN 02528681 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01900978
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (04:00 ANTIHISTAMINES) and how they are covered

Matched class: 04:00 ANTIHISTAMINES

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. No displayed product is listed as a general benefit in this extract. Check its listing requirements below. 04:00 ANTIHISTAMINES

BILASTINE

· 12 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2.5mg/mL, 20mg · Oral Sol, Tab

LORATADINE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg · Tab

RUPATADINE

· 4 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 04:00
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS Adults and children 12 years of age and over: REACTINE® 20 mg Tablet (cetirizine hydrochloride) is indicated: • for the fast relief of nasal and non-nasal symptoms associated with seasonal and perennial allergic rhinitis (i.e. sneezing, rhinorrhea, post-nasal discharge, nasal congestion/stuffiness, tearing and redness of the eyes, itchy nose/throat) and chronic idiopathic urticaria (e.g. pruritus and hives). 1.1 Pediatrics Pediatrics - Children <12 years of age: REACTINE® 20 mg Tablet is not recommended in children less than 12 years of age, as safety and efficacy have not been established in this age group. 1.2 Geriatrics Geriatrics: Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness and a brief discussion can be found in the appropriate sections (See Warning and Precautions, Special Populations- Geriatrics). REACTINE® 20 mg Tablet is not recommended in patients 65 years and older. The recommended starting dose is 5 mg once daily. https://pdf.hres.ca/dpd_pm/00084353.PDF PM date: APR 17, 2026 Source product: REACTINE 20 MG TABLET; DIN 01900978; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Reactine: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026